Soligenix jumps on FDA's orphan drug tag for Behcet's disease therapy
Brief: Soligenix Inc Receives Nasdaq Notice For Non-Compliance With Equity Requirement
Soligenix Inc reports results for the quarter ended June 30 - Earnings Summary
Soligenix Inc expected to post a loss of 92 cents a share - Earnings Preview
Brief: Biological Efficacy Demonstrated In A Phase 2 Clinical Trial Of Sgx945 For The Treatment Of Behçet's Disease
Soligenix Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Soligenix Inc - Positive Outcome In 75% Of Ctcl Patients Treated With Hybryte For 18 Weeks
Brief: Soligenix Announces Publication Demonstrating CiVax™ Booster Induces Rapid Broad Protection Against COVID-19 Variants
Soligenix Inc reports results for the quarter ended December 31 - Earnings Summary
Soligenix Inc expected to post a loss of 95 cents a share - Earnings Preview
Soligenix Inc expected to post a loss of 95 cents a share - Earnings Preview
Brief: HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma
Brief: HyBryte Clinical Results Demonstrate Continued Improvement Post-Treatment
Brief: Soligenix Announces Formation Of European Medical Advisory Board For Cutaneous T-Cell Lymphoma
Soligenix Inc expected to post a loss of $1.09 a share - Earnings Preview
Brief: Soligenix Receives Hong Kong Patent For Improved Production Of Synthetic Hypericin
U.S. STOCKS ON THE MOVE-Dyne Therapeutics, Maxeon Solar, chip stocks
U.S. STOCKS ON THE MOVE-Walgreens, Copper miners, Simon Property
U.S. STOCKS ON THE MOVE-Boeing, Southwest Airlines, PDD Holdings